{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:44:55Z","timestamp":1776455095945,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.pharmthera.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T05:10:06Z","timestamp":1428556206000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Bivalirudin in stable angina and acute coronary syndromes"],"prefix":"10.1016","volume":"152","author":[{"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiannis S.","family":"Chatzizisis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.04.003_bb0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/1755-5922.12068","article-title":"Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry","volume":"32","author":"Alexopoulos","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb9000","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCINTERVENTIONS.111.961912","article-title":"Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry","volume":"4","author":"Bangalore","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0020","doi-asserted-by":"crossref","first-page":"g6419","DOI":"10.1136\/bmj.g6419","article-title":"Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: A meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors","volume":"349","author":"Bangalore","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2165\/11205120-000000000-00000","article-title":"Bivalirudin: in patients with ST-segment elevation myocardial infarction","volume":"70","author":"Curran","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0040","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2011.01.038","article-title":"Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: The HORIZONS-SWITCH analysis","volume":"57","author":"Dangas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0050","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial","volume":"47","author":"Gibson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0055","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijcard.2014.03.003","article-title":"Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry","volume":"173","author":"Hamon","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction. The BRIGHT randomized clinical trial","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/CIRCINTERVENTIONS.112.968966","article-title":"Bivalirudin for primary percutaneous coronary interventions: Outcome assessment in the Ottawa STEMI registry","volume":"5","author":"Hibbert","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199222050-00003","article-title":"Heparin pharmacokinetics and pharmacodynamics","volume":"22","author":"Kandrotas","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0080","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0085","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0090","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1213\/01.ANE.0000057605.61063.55","article-title":"An assessment of different filter systems for extracorporeal elimination of bivalirudin: An in vitro study","volume":"96","author":"Koster","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0095","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCULATIONAHA.105.587758","article-title":"Blocking the protease-activated receptor 1\u20134 heterodimer in platelet-mediated thrombosis","volume":"113","author":"Leger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0105","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0110","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)","volume":"93","author":"Lincoff","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0120","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.amjcard.2014.04.033","article-title":"Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction","volume":"114","author":"Nairooz","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0130","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/CIRCINTERVENTIONS.112.972869","volume":"5","author":"Ndrepepa","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","volume":"110","author":"Patti","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0140","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1592\/phco.22.10.105S.33616","article-title":"Clinical pharmacology of bivalirudin","volume":"22","author":"Reed","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0145","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4244\/EIJV9I4A71","article-title":"One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: Updated results from the ISAR-REACT 4 trial","volume":"9","author":"Schulz","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0150","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","volume":"35","author":"Schulz","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0155","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1368-5031.2005.00823.x","article-title":"Clinical development of bivalirudin (Angiox): Rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes","volume":"60","author":"Serruys","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0160","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0165","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2013.09.027","article-title":"Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0170","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention. Pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials","volume":"65","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0175","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","article-title":"Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial","volume":"298","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0185","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0190","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0205","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0210","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.amjcard.2009.06.035","article-title":"Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention","volume":"104","author":"Tavano","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0215","series-title":"Summary of product characteristics: Angiox (bivalirudin)","author":"The Medicines Company","year":"2009"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0220","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","article-title":"Third universal definition of myocardial infarction","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12265-013-9537-1","article-title":"Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial","volume":"7","author":"Valgimigli","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/joic.12005","volume":"26","author":"Waksman","year":"2013","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0235","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0240","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jacc.2007.12.052","volume":"51","author":"White","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.04.003_bb0245","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.amjcard.2013.05.006","article-title":"Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery","volume":"112","author":"W\u00f6hrle","year":"2013","journal-title":"Am J Cardiol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T01:11:48Z","timestamp":1566522708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":49,"alternative-id":["S0163725815000789"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.04.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalirudin in stable angina and acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}